Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Bio-Techne (TECH) to $51 from $68 and keeps an Outperform rating on the shares. The firm upated its model ahead of its Q3 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Novavax slides after RFK Jr. casts doubts about COVID vaccine
- Apple, Starbucks upgraded: Wall Street’s top analyst calls
- Bio-Techne downgraded to Sector Weight from Overweight at KeyBanc
- Bio-Techne price target lowered to $72 from $79 at RBC Capital
- Bio-Techne expands partnership with Leica Biosystems